Skip to main content

VESIcare (solifenacin) Disease Interactions

There are 7 disease interactions with VESIcare (solifenacin):

Major

Solifenacin (applies to VESIcare) GI motility

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of solifenacin is contraindicated in patients with gastric retention. Caution is advised even when using this agent in patients with decreased gastrointestinal motility.

Major

Solifenacin (applies to VESIcare) kidney impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Solifenacin should be used with caution in patients with renal impairment. Increase in half-life and AUC have been demonstrated in patients with severe renal impairment. Caution should be taken when prescribing this agent to patients with renal impairment. Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.

Major

Solifenacin (applies to VESIcare) liver impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Solifenacin should be used with caution in patients with reduced hepatic function. Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment. Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer. Solifenacin is not recommended in patients with severe hepatic impairment. .

Major

Solifenacin (applies to VESIcare) narrow-angle glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma (Narrow Angle)

The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma. Caution is advised even when using this agent in patients with narrow-angle glaucoma.

Major

Solifenacin (applies to VESIcare) urinary obstruction

Major Potential Hazard, High plausibility. Applicable conditions: Urinary Retention

The use of solifenacin is contraindicated in patients with urinary retention. Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.

Moderate

Solifenacin (applies to VESIcare) CNS

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: CNS Disorder, Dementia

Solifenacin is associated with anticholinergic central nervous system (CNS) effects. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered. Solifenacin should be used with caution in patients with Parkinson's disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.

Moderate

Solifenacin (applies to VESIcare) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Dose dependent prolongation in QT interval has been observed with the use of solifenacin. This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.

VESIcare (solifenacin) drug interactions

There are 453 drug interactions with VESIcare (solifenacin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.